The estimated Net Worth of Inc Amgen is at least $4 Billion dollars as of 10 September 2021. Inc Amgen owns over 165,529 units of BeiGene Ltd stock worth over $3,999,983,792 and over the last 4 years Inc sold BGNE stock worth over $0.
Inc has made over 1 trades of the BeiGene Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently Inc bought 165,529 units of BGNE stock worth $49,999,690 on 10 September 2021.
The largest trade Inc's ever made was buying 165,529 units of BeiGene Ltd stock on 10 September 2021 worth over $49,999,690. On average, Inc trades about 23,647 units every 0 days since 2020. As of 10 September 2021 Inc still owns at least 18,943,802 units of BeiGene Ltd stock.
You can see the complete history of Inc Amgen stock trades at the bottom of the page.
Inc's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: